Cargando…
Is sitagliptin effective for the treatment of COVID-19?
Autores principales: | Memiş, Hasan, Çakır, Ahmet, DURMUŞ, Mefküre, GÖK, Selim, Bahçeciȯğlu, Ömer Faruk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614154/ https://www.ncbi.nlm.nih.gov/pubmed/33504509 http://dx.doi.org/10.1136/ejhpharm-2021-002702 |
Ejemplares similares
-
Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
por: Bahçecíoğlu, Ömer Faruk, et al.
Publicado: (2021) -
Benefit versus toxicity risk of digoxin in patients with COVID-19
por: Kelleci Cakir, Burcu, et al.
Publicado: (2022) -
Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?
por: Yalçın, Nadir, et al.
Publicado: (2021) -
Tocilizumab in COVID-19 management: addressing time of starting treatment
por: Khiali, Sajad, et al.
Publicado: (2023) -
COVID-19 and education in regional anesthesia
por: Ríos Medina, Angela María, et al.
Publicado: (2021)